(Total Views: 559)
Posted On: 02/06/2022 9:01:12 PM
Post# of 36541
AE37 as a breast cancer vaccine for Triple Negative patients is mentioned in context of a much broader research article about peptide vaccines for breast cancer. I hope we find life and Dr. EvH can get back to setting up research for Ii-Key which stalled badly since 2017. Jmho, but I wouldn’t put $1.5M into a building in Texas, I’d put it into efforts of Rich Purcell in advancing Ii-Key. (I’ll take any sign of life however.)
One snippet in the Conclusion:
“Moreover, the results of different peptide vaccines indicate that vaccine formulations should be tailored to the features of the tumor being targeted. Tolerance might be avoided by using subdominant epitopes with lower binding affinity against antigens with higher expression levels. For instance, E75, a dominant epitope of HER2, appears most effective in tumors expressing low degrees of HER2, while GP2, a subdominant epitope of HER2, shows more potential in HER2-overexpressing breast cancer in combination with trastuzumab. AE37, the MHC class-II targeted vaccine, shows the greatest efficacy in TNBC and may be helpful in all HLA subtypes (137).
https://www.frontiersin.org/articles/10.3389/...28386/full
One snippet in the Conclusion:
“Moreover, the results of different peptide vaccines indicate that vaccine formulations should be tailored to the features of the tumor being targeted. Tolerance might be avoided by using subdominant epitopes with lower binding affinity against antigens with higher expression levels. For instance, E75, a dominant epitope of HER2, appears most effective in tumors expressing low degrees of HER2, while GP2, a subdominant epitope of HER2, shows more potential in HER2-overexpressing breast cancer in combination with trastuzumab. AE37, the MHC class-II targeted vaccine, shows the greatest efficacy in TNBC and may be helpful in all HLA subtypes (137).
https://www.frontiersin.org/articles/10.3389/...28386/full
(4)
(0)Scroll down for more posts ▼
